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Abstract 
Our previous studies revealed that a single Wilms’ tumor 1 (WT-1) immunohistochemistry 
can be used to elucidate both the myoepithelial cells and blood vessels of human breast 
tumors. As the human ovary is rich in blood vessels, and WT-1 has been used as a biomarker 
for ovarian tumors, our current study attempted to assess if a single WT-1 immunohisto-
chemistry has dual usages in evaluation of ovarian tumor and endothelial cells. Paraf-
fin-embedded tissue sections were prepared from 20 cases of ovarian tumors. A set of four 
consecutive sections from each case were subjected to immunohistochemistry with a mouse 
monoclonal antibody against the human WT-1 protein, a well defined ovarian tumor marker, 
CA-125, and a endothelial cell phenotypic marker, CD34, respectively. From each case, 4-5 
randomly selected fields were photographed, and expression of these molecules in the same 
structures were compared. Distinct WT-1 immunoreactivities were seen in both ovarian 
tumor and endothelial cells. Over 90% of WT-1 positive tumor and endothelial cells were 
positive for CA-125 and CD34, respectively. Similarly, over 90% of CA-125 or CD34 positive 
cells co-express WT-1 in tumor or endothelial cells, respectively. Our findings suggest that a 
single WT-1 immunohistochemistry can be used to assess both the tumor cells and mi-
cro-vascular density in ovarian tumors. Our findings also suggest that as WT-1 is expressed in 
both tumor and endothelial cells, the development of therapeutic agents to target WT-1 may 
provide an effective treatment option for ovarian cancer.  
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Introduction 
The Wilms’ tumor 1 (WT-1) gene is located at 
chromosome 11p13, and is encoded by 10 exons, re-
sulting in a WT-1 mRNA with a complex pattern of 
alternative splicing [1-5]. The WT-1 encodes a tran-
scription factor of the zinc-finger family, which binds 
to GC-rich sequences and regulates the expression of 
several genes of the growth factor family, including 
the insulin-like growth factor and transforming 
growth factor [1-5]. The WT-1 protein is preferentially 
expressed in the genitourinary system and aberrant 
expression of the WT-1 protein has been implicated in 
the development of Wilms’ tumors in this system 
[1-5]. Recent studies have further shown that aberrant 
expression of the WT-1 protein may also be closely Journal of Cancer 2010, 1 
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associated with the development and progression of 
other malignancies, including mesothelioma, leuke-
mia, and breast, esophageal, colorectal tumors [6-11]. 
Our own studies have consistently demonstrated that 
the WT-1 protein is preferentially present in breast 
myoepithelial and endothelial cells, and have shown 
that a single WT-1 immunohistochemistry can have 
dual use in evaluation of breast tumors [12,13].  
As the human ovary is rich in blood vessels and 
WT-1 has been used as a biomarker for ovarian tu-
mors [14-16], our current study attempted to test a 
hypothesis that WT-1 is co-expressed with a well de-
fined ovarian tumor marker, CA125 [17-19], and also 
with a endothelial cell phenotypic marker, CD34, in 
the same cells. Therefore, a single WT-1 immunohis-
tochemistry may have dual usages in evaluation of 
both the ovarian tumor cells and also the vascular 
density of the ovarian tissues.  
Materials and Methods 
  Formalin-fixed, paraffin-embedded ovarian tis-
sue blocks from 20-patients were retrieved from the 
files of the Armed Forces Institute of Pathology. Each 
of the tumors harbored normal and malignant tissue 
components. As the sole purpose of this study was to 
assess the overall expression of WT-1 in tumor and 
endothelial ells, the clinical profile was not collected 
and evaluated.  
  Consecutive sections at 4-5 μm thickness were 
cut and placed on positively charged slides. A set of 
four consecutive sections from each case were sub-
jected to immunohistochemistry with mouse monoc-
lonal antibodies against the human WT-1 protein 
(6F-H2; Cell Marque, Hot Springs, AR),the ovarian 
specific antigen CA-125 (Ov185:1; Lab Vision, Fre-
mont, CA), the WT-1, and an endothelial cell marker, 
CD 34 (Vector, Burlingame, CA), according to the 
protocols provided by manufacturers. From each case, 
4-5 fields with tumor cells were randomly selected 
and photographed, and enlarged prints were made. 
The numbers of positive and negative tumor or en-
dothelial cells within the same structure (a tumor nest 
or blood vessel) were counted and the percentage of 
positive cells was calculated. Co-expression of WT-1 
with CA-125 or CD34 was evaluated in two ways: (1) 
2-3 prints with distinct WT-1 positive immunostain-
ing were first selected from each case and used as 
positive controls to compare the expression of CA-125 
and CD34 in adjacent sections, and (2) 1-2 prints with 
distinct CA-125 or CD34 immunostaining were first 
identified from each case and used as positive con-
trols to compare the expression of WT-1 in adjacent 
sections. Co-expression of WT-1 with CA-125 or CD34 
was defined as the presence of these molecules within 
identical cells at the adjacent sections.  
To assess the specificity of the immunostaining, 
different controls were used, which included: (1) the 
substitution of the primary antibody with the normal 
serum, (2) the omission of the secondary antibody, (3) 
and serial dilutions of the primary antibody. All the 
immunostainings was repeated at least twice under 
the same condition. Immunostained sections were 
independently evaluated by investigators. A cell was 
considered positive if distinct immunoreactivities 
were consistently present in its cytoplasm or nucleus 
in all the repeated staining processes, whereas all 
negative controls were completely devoid of immu-
noreactivities.  
Results 
All negative controls were completely devoid of 
distinct immunoreactivities to WT-1, CA-125, and 
CD34. Distinct nuclear WT-1 expression was exclu-
sively or preferentially seen in serous tumor cells, 
while both nuclear and/or cytoplasmic WT-1 expres-
sion was present in morphologically distinct endo-
thelial cells in each of the cases, with weak and diffuse 
staining occasionally seen in some fibroblasts and 
white blood cells. CA-125 immunoreactivities were 
exclusively or preferentially seen in the surface plas-
ma membrane of tumor cells. CD34 expression is seen 
mainly in the cytoplasm of endothelial cells.  
The overall expression pattern and frequency of 
WT-1 and CA-125, or WT-1 and CD34, were very 
similar in all 94-randomly selected fields. Over 3,000 
WT-1 positive tumor cells counted, 90.4% showed 
distinct CA-125 expression in the adjacent section (Fig 
1). Over 3,000 CA-125 positive tumor cells counted, 
90.3% showed distinct WT-1 expression in the adja-
cent section (Fig 2). Similarly, over 90% of the WT-1 or 
CD34 positive endothelial cells showed distinct ex-
pression of their counterparts in the adjacent sections 
(Figs 1-2).  Journal of Cancer 2010, 1 
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Figure 1: WT-1 positive cells co-express CA-125 and CD34. A set of 4-consecutive sections were immunostained for 
WT-1, CA-125, and CD34. Circles identify tumor cell clusters with WT-1 and CA-125 expression. Arrows identify small 
blood vessels. Note that a vast majority of WT-1 positive cells co-express CA-125 or CD34, and that WT-1 expression was 
consistent in different sections. a, c, e, and g: 100X. b, d, f, and h: a higher (300X) magnification of a, c, e, and g, respectively.  Journal of Cancer 2010, 1 
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Figure 2: CA-125 or CD 34 positive cells co-express WT-1. A set of 4-consecutive sections were immunostained for 
CA-125, CD34, and WT-1. Circles identify tumor cell clusters with WT-1 and CA-125 expression. Arrows identify small 
blood vessels. Note that a vast majority of CA-125 or CD34 positive tumor or endothelial cells co-express WT-1, and that 
WT-1 expression was consistent in different sections. a, c, e, and g: 100X. b, d, f, and h: a higher (300X) magnification of a, 
c, e, and g, respectively. Journal of Cancer 2010, 1 
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Discussion and Conclusions 
 Our current study revealed that: (1) over 90% of 
WT-1 positive tumor cells co-expressed CA-125, (2) 
over 90% of WT-1 positive endothelial cells 
co-expressed CD34, and (3) over 90% of the CA-125 or 
CD34 positive cells co-expressed their counterpart 
molecule WT-1 in tumor and endothelial cells, re-
spectively. Our finding of WT-1 expression in ovarian 
tumor cells is consistent with a number of previous 
studies, which have shown that WT-1 is a useful 
marker for elucidation of ovarian tumor cells [14-16]. 
Our finding of WT-1 expression in endothelial cells is 
in total agreement with that of our previous study in 
human breast tumors [13] and is also consistent with 
that of a recent study, which reported that “Endo-
thelial WT-1 expression was detected in 95% of 113 
tumors of different origin” [20]. Together, these find-
ings suggest that a single WT-1 immunohistochemi-
stry have dual usages in evaluation of both ovarian 
tumor cells and the vascular density. These findings 
also suggest that as WT-1 is heavily expressed in both 
tumor and endothelial cells, the development of the-
rapeutic agents to specifically target WT-1 may pro-
vide an effective treatment option for ovarian cancer.  
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